Earnings
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials.
Multiple pharma company stocks make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.
German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter’s lead program, AMT-260, an advanced treatment for TLE.
There’s plenty of money on the move as venture capital firms and investors look to the future of biotech. Read on for today’s top Series A rounds.
It’s been a bumpy ride for Biogen as news swirls around its overall Alzheimer’s program… but not for its competitors with investigational therapies for that disease.
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.
PRESS RELEASES